Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, follitropin delta (Rekovelle®) cannot be endorsed for use within NHS Wales for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with Rekovelle in the long GnRH agonist protocol. |
||
|
||
Medicine details |
||
| Medicine name | follitropin delta (Rekovelle®) | |
| Formulation | 12 mg/0.36 ml, 36 mg/1.08 ml and 72 mg/2.16 ml solution for injection | |
| Reference number | 2974 | |
| Indication | Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle. There is no clinical trial experience with Rekovelle in the long GnRH agonist protocol |
|
| Company | Ferring Pharmaceuticals (UK) | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 12/07/2017 | |